Skip to content

Construction and empirical research of evidence integration system and evaluation system based on big data

Construction and empirical research of evidence integration system and evaluation system based on big data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079646
Enrollment
Unknown
Registered
2024-01-08
Start date
2024-01-09
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the respiratory system

Interventions

Case series:none

Sponsors

Sichuan University, West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with asthma • Age= 18 years, regardless of gender; • The diagnostic criteria for asthma are in line with GINA and China's guidelines for asthma diagnosis and treatment; • In the stable stage of asthma, i.e., no change in maintenance treatment regimen in the 4 weeks prior to enrollment, no respiratory tract infection or/and asthma exacerbation; • Voluntarily participate and sign the informed consent form. Inclusion criteria for patients with severe asthma (SA). • Confirm evidence of any of the following variable airflow obstruction (VAO) at the screening visit or in the last 10 years of medical records: including: 1. Positive Bronchial Challenge Test (BCT): FEV1 decreased by =20% compared with before bronchial provotion; 2. Positive Bronchial Dilation Test (BDT): FEV1 increased by =12% compared with before bronchodilator, and its absolute value increased by =200ml; 3. Peak expiratory flow rate (PEF) variability > 12%, monitored for at least 1 week; 4. FEV1 mutation rate>12% (between 2 measurements within 2 months); • Patients are unable to achieve asthma control despite the use of GINA grade 4-5 recommended therapy (eg, high-dose ICS, budesonide > 800 µg, fluticasone > 500 µg); • Asthma control can only be maintained with the recommended treatment of GINA grade 4-5 such as high-dose ICS, budesonide >800 µg, fluticasone >500 µg); Inclusion criteria for patients with non-severe asthma (NSA). • Use of maintenance doses of inhaled controlled therapeutic drugs; • Asthma is under control, i.e. ACQ 20;

Exclusion criteria

Exclusion criteria: • Those who have undergone heart, lung or thoracic surgery; • Pregnant or lactating women; • Those who cannot cooperate with sputum induction and pulmonary function operators

Design outcomes

Primary

MeasureTime frame
Endotracheal intubation;

Countries

China

Contacts

Public ContactDeYing Kang

Sichuan University, West China Hospital

deyingkang@126.com+86 189 8060 1799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026